125 related articles for article (PubMed ID: 17580370)
21. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
22. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
Singh AK
J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
[No Abstract] [Full Text] [Related]
23. [The use of erythropoietin in HIV myelodysplasias. Preliminary study].
Fruttaldo L; Gatti G; Deambrogio V; Mongiò F; Schettino G; Cavagnolo G
Minerva Med; 1993 Mar; 84(3):103-5. PubMed ID: 8492960
[TBL] [Abstract][Full Text] [Related]
24. Erythropoietin: the swinging pendulum.
Oster HS; Neumann D; Hoffman M; Mittelman M
Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365
[TBL] [Abstract][Full Text] [Related]
25. FDA notifications. FDA approval for generic lamivudine/zidovudine.
AIDS Alert; 2008 Jan; 23(1):12. PubMed ID: 18572476
[No Abstract] [Full Text] [Related]
26. Changes for ESAs.
Spalding BJ
Nat Biotechnol; 2008 May; 26(5):483. PubMed ID: 18464763
[No Abstract] [Full Text] [Related]
27. Epoetin alfa and darbepoetin alfa go head to head.
Steensma DP; Loprinzi CL
J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
[No Abstract] [Full Text] [Related]
28. FDA notifications. Tentative approval of India-made zidovudine.
AIDS Alert; 2005 Sep; 20(9):108. PubMed ID: 16206404
[No Abstract] [Full Text] [Related]
29. FDA notifications. Abacavir package insert changes approved. Hypersensitivity, other issues addressed.
AIDS Alert; 2008 Sep; 23(9):102-4. PubMed ID: 18939305
[No Abstract] [Full Text] [Related]
30. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
31. FDA notifications. FDA changes information for stavudine label.
AIDS Alert; 2002 May; 17(5):67. PubMed ID: 12030220
[No Abstract] [Full Text] [Related]
32. FDA sounds alert on anemia drugs.
Mitka M
JAMA; 2007 May; 297(17):1868-9. PubMed ID: 17473287
[No Abstract] [Full Text] [Related]
33. FDA notifications. Zidovudine approved for pediatric use.
AIDS Alert; 2009 Sep; 24(9):105. PubMed ID: 19928325
[No Abstract] [Full Text] [Related]
34. [Recent advances on the use of erythropoietin in oncology].
Spaëth D
Bull Cancer; 2006 May; 93(5):489-93. PubMed ID: 16777627
[TBL] [Abstract][Full Text] [Related]
35. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Waltzman RJ
Cancer; 2004 Apr; 100(7):1545-6; author reply 1546. PubMed ID: 15042691
[No Abstract] [Full Text] [Related]
36. FDA notifications. Tentative approval for generic lamivudine/zidovudine.
AIDS Alert; 2007 Oct; 22(10):119-20. PubMed ID: 18416011
[No Abstract] [Full Text] [Related]
37. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
McGahan L
Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
[TBL] [Abstract][Full Text] [Related]
38. FDA notifications. Gilead issues letter about virologic failure.
AIDS Alert; 2003 Dec; 18(12):159-60. PubMed ID: 14696542
[No Abstract] [Full Text] [Related]
39. FDA notifications. Rare complication with didanosine.
AIDS Alert; 2010 Apr; 25(4):46-8. PubMed ID: 20560192
[No Abstract] [Full Text] [Related]
40. Erythropoietin: high profile, high scrutiny.
Crawford J
J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
